Introduction
============

Prostate cancer is the second leading incident cancer after lung cancer and the sixth leading cause of cancer mortality in men globally.[@b1-cmo-8-2014-029] Metastatic castration-resistant prostate cancer (mCRPC) is defined as persistent tumor proliferation despite castrate testosterone levels, not responding to standard surgical or medical androgen-deprivation therapy, with bone being the most common organ site of metastatic disease.[@b2-cmo-8-2014-029],[@b3-cmo-8-2014-029]

A combination of mitoxantrone and prednisone had previously been the standard of care for treatment of mCRPC. Following landmark trials that demonstrated the superiority of docetaxel over mitoxantrone, docetaxel plus prednisone emerged as the standard of care for first-line therapy for mCRPC.[@b4-cmo-8-2014-029]--[@b6-cmo-8-2014-029] Nevertheless, patients treated with docetaxel commonly develop progression or relapse and hence, the availability of second-line therapeutic options remains pivotal. More recently, the TROPIC trial has reported superiority in overall survival (OS) of cabazitaxel (a second-generation taxane) plus prednisone over mitoxantrone plus prednisone in post-docetaxel mCRPC patients.[@b7-cmo-8-2014-029]

Tumor biology indicates that despite castrate levels of testosterone, signaling in hormone-related pathways remains a critical driver in prostate cancer progression including (a) upregulation of androgen-producing enzymes, (b) genetic modifications stimulating upregulation of androgen-receptors, and (c) androgen-receptor mutations enabling cross-talk activation by mediators.[@b8-cmo-8-2014-029]--[@b10-cmo-8-2014-029]

Recent basic research has provided insights into the molecular mechanisms of mCRPC. A two-compartment model describes the prostate tumor epithelial compartment interaction with its microenvironment stromal compartment. The cross-talk between these two compartments contributes to progression of mCRPC through signaling mechanisms of the androgenic, tyrosine kinase, angiogenic, apoptotic, and immune pathways.[@b11-cmo-8-2014-029]--[@b14-cmo-8-2014-029]

As a consequence of a more thorough understanding of prostate cancer biology and molecular mechanisms, novel hormonal therapeutic targets for post-docetaxel mCRPC have recently been tested in phase III trials: enzalutamide[@b15-cmo-8-2014-029] and abiraterone acetate.[@b16-cmo-8-2014-029],[@b17-cmo-8-2014-029]

Enzalutamide (MDV3100) is an oral androgen-receptor blocker that binds more tightly and has a novel mechanism of action compared to older anti-androgens. It is thought to work by disrupting androgen-receptor nuclear translocation, binding of hormone response elements, and subsequent mobilization of regulatory proteins for downstream transcription and translation.[@b11-cmo-8-2014-029],[@b18-cmo-8-2014-029] The phase 3 AFFIRM trial compared enzalutamide to placebo, potentially with prednisone or other glucocorticoids, and demonstrated superiority in all outcomes, including OS, time to prostate-specific-antigen (PSA) progression, radiographic progression-free survival (PFS), and PSA RR.[@b15-cmo-8-2014-029]

Abiraterone acetate is a pro-drug developed for oral administration. Its metabolite, abiraterone, is a CYP17 inhibitor in the steroidogenesis pathway, which is believed to work primarily through inhibition of 17α-hydroxylase and c17,20-lyase. This in turn inhibits production of dehydroepiandrostenedione (DHEA) and androstenedione, precursors of testosterone.[@b19-cmo-8-2014-029] The phase 3 COU-AA-301 trial compared abiraterone acetate plus prednisone versus placebo plus prednisone and demonstrated superiority in all outcomes, including OS, time to PSA progression, radiographic PFS, and PSA response rate (RR).[@b16-cmo-8-2014-029],[@b17-cmo-8-2014-029]

A recent meta-analysis by Iacovelli et al has demonstrated significant improvement in OS for second-line treatment of mCRPC using pooled data on cabazitaxel, abiraterone acetate, and enzalutamide with their respective comparators.[@b20-cmo-8-2014-029] Unfortunately, there is no currently available phase 3 data directly comparing the effectiveness of hormonal therapeutics enzalutamide to abiraterone acetate in patients with post-docetaxel mCRPC. Hence, we aim to perform a literature-based systematic review and make an indirect comparison of hormonal therapeutics between enzalutamide and abiraterone acetate in terms of OS, time to PSA progression, radiographic PFS, PSA RRs, and adverse events.

Methods
=======

Study selection
---------------

Randomized phase III clinical trials having hormonal therapeutics enzalutamide or abiraterone acetate as a comparator in mCRPC patients post-docetaxel were included. Endpoints of interest were OS, time to PSA progression, radiographic PFS, PSA RRs, and adverse events. Literature search was performed with PubMed to identify published randomized phase 3 trials using the search phrase "enzalutamide" OR "abiraterone". The search results were further limited to clinical trials. Abstracts were screened, and non-relevant studies were excluded.

As an assessment of risk of publication bias, [clinical-trials.gov](http://clinical-trials.gov) was searched for any registered trials using either enzalutamide or abiraterone and having accessible results. As an assessment of risk of bias within the included studies, each study's design and execution were examined in terms of patient selection, interventions applied to study arms, loss to follow-up, endpoint assessment, and reporting.

Statistical analysis
--------------------

Indirect comparisons are increasingly used to draw preliminary insights based on the best available evidence for comparative effectiveness of interventions when direct head-to-head comparisons are not available.[@b21-cmo-8-2014-029]--[@b23-cmo-8-2014-029]

Indirect comparisons of enzalutamide to abiraterone acetate on each outcome, OS, time to PSA progression, radiographic PFS, and PSA response, in terms of hazard or odds ratios, as appropriate, were constructed in the context of log-linear regression models with standard errors fixed at those respectively reported in the enzalutamide versus placebo (AFFIRM)[@b15-cmo-8-2014-029] and abiraterone acetate versus placebo (COU-AA-301)[@b17-cmo-8-2014-029] studies. Owing to lack of replication of comparisons, it was not possible to estimate study-to-study heterogeneity, and the primary estimates are subject to the assumption of no heterogeneity in treatment effects across studies. However, the potential impact of a broad range of heterogeneity scenarios was examined in a sensitivity analysis.

Where alike adverse events were reported in both studies, indirect comparisons of adverse event rates were generated using methods similar to RR. In the case of drug-specific adverse events, individual odds ratios for comparison with placebo were computed using rates reported in the individual studies.

As there was only one study for each treatment comparison, it was not possible to estimate study-to-study heterogeneity. Hence, we performed a sensitivity analysis to assess the robustness of our results to a range of heterogeneity scenarios in terms of *I*[@b2-cmo-8-2014-029], the proportion of variability across studies which is because of actual study-specific differences in treatment effect rather than chance.[@b24-cmo-8-2014-029],[@b25-cmo-8-2014-029] In the context of a mixed model for meta-analysis similar to DerSimonian and Laird,[@b26-cmo-8-2014-029] it can be shown that if the estimates of the included studies have similar standard errors, then study-to-study variance is approximately (*I*[@b2-cmo-8-2014-029]/(1 − *I*[@b2-cmo-8-2014-029]))SE[@b2-cmo-8-2014-029]. To assess the sensitivity of results to potential study-to-study heterogeneity, for each outcome, *I*[@b2-cmo-8-2014-029] was varied over (0, 25, 50, 75%) whereas SE[@b2-cmo-8-2014-029] was set at its average value over AFFIRM[@b15-cmo-8-2014-029] and COU-AA-301.[@b17-cmo-8-2014-029] Then, 95% confidence intervals (95% CIs) and 95% predictive intervals (95% PIs) were constructed in the context of log-linear mixed models with study-to-study variance set using the above equation.

A further sensitivity analysis was performed by comparing indirect estimates obtained with comparison of AFFIRM[@b15-cmo-8-2014-029] to COU-AA-301[@b17-cmo-8-2014-029] in the full analysis to those obtained with comparison of AFFIRM[@b15-cmo-8-2014-029] to COU-AA-301[@b16-cmo-8-2014-029] in the interim analysis.

Results
=======

The methods and results of this indirect comparison are reported in accordance with PRISMA guidelines.[@b27-cmo-8-2014-029] Literature search yielded two published randomized phase 3 trials that fulfilled the search criteria of a trial containing an experimental arm with either enzalutamide or abiraterone as treatment of patients with mCRPC post-docetaxel ([Fig. 1](#f1-cmo-8-2014-029){ref-type="fig"}). Results from the AFFIRM[@b15-cmo-8-2014-029] and COU-AA-301[@b17-cmo-8-2014-029] trials comparing enzalutamide to placebo and abiraterone acetate to placebo, respectively, were used to indirectly compare enzalutamide to abiraterone acetate. [Table 1](#t1-cmo-8-2014-029){ref-type="table"} summarizes each study.

OS
--

The hazard ratios (HRs) (95% CIs) in the AFFIRM[@b15-cmo-8-2014-029] and COU-AA-301[@b17-cmo-8-2014-029] trials for OS for enzalutamide versus placebo and abiraterone acetate versus placebo were 0.63 (0.53--0.75) and 0.74 (0.64--0.86), respectively. The indirect estimate of the HR (95% CI; *P*-value) for enzalutamide versus abiraterone acetate was 0.85 (0.68--1.07; *P* = 0.17) as illustrated in [Figure 2](#f2-cmo-8-2014-029){ref-type="fig"}.

Time to PSA progression
-----------------------

The HRs (95% CIs) in the AFFIRM[@b15-cmo-8-2014-029] and COU-AA-301[@b17-cmo-8-2014-029] trials for time to PSA progression for enzalutamide versus placebo and abiraterone acetate versus placebo were 0.25 (0.20--0.30) and 0.63 (0.52--0.78), respectively. The indirect estimate of the HR (95% CIs; *P*-value) for enzalutamide versus abiraterone acetate was 0.40 (0.30--0.53; *P* \< 0.001) as illustrated in [Figure 3](#f3-cmo-8-2014-029){ref-type="fig"}.

Radiographic PFS
----------------

The respective HRs (95% CIs) in the AFFIRM[@b15-cmo-8-2014-029] and COU-AA-301[@b17-cmo-8-2014-029] trials for radiographic PFS for enzalutamide versus placebo and abiraterone acetate versus placebo were 0.40 (0.35--0.47) and 0.66 (0.58--0.76), respectively. The indirect estimate of the HR (95% CIs; *P*-value) for enzalutamide versus abiraterone acetate was 0.61 (0.50--0.74; *P* \< 0.001) as illustrated in [Figure 4](#f4-cmo-8-2014-029){ref-type="fig"}.

PSA response
------------

The odds ratios (95% CIs) in the AFFIRM[@b15-cmo-8-2014-029] and COU-AA-301[@b17-cmo-8-2014-029] trials for PSA response for enzalutamide versus placebo and abiraterone acetate versus placebo were 76.41 (31.22--187.04) and 7.15 (4.53--11.28), respectively. The indirect estimate of the odds ratio (95% CIs; *P*-value) for enzalutamide versus abiraterone acetate was 10.69 (3.92--29.20; *P* \< 0.001) as illustrated in [Figure 5](#f5-cmo-8-2014-029){ref-type="fig"}.

Adverse events
--------------

There were no statistically significant differences in fatigue, diarrhea, or liver function abnormalities with enzalutamide versus abiraterone acetate, albeit marginally more cardiac disorders with abiraterone acetate. Specific adverse events from abiraterone acetate include fluid retention and hypokalemia, which were significantly more common in the treatment group compared to placebo. In all, 5 of 800 patients treated with enzalutamide had seizures while no patients in the placebo group did ([Table 2](#t2-cmo-8-2014-029){ref-type="table"}).

Assessment of risk of publication bias and within included study bias
---------------------------------------------------------------------

Search of [clinicaltrials.gov](http://clinicaltrials.gov) for registered clinical trials using either enzalutamide or abiraterone for the same indication did not yield any additional relevant studies.[@b28-cmo-8-2014-029],[@b29-cmo-8-2014-029] We conclude that the risk of publication bias is low. In both included studies, well-defined and similar patient populations were recruited. Both trials were randomized, double blind, and placebo controlled. In both, intention-to-treat estimates were reported. We conclude that the risk of bias within the included studies is also low.

Sensitivity analyses
--------------------

Sensitivity analysis of the robustness of our results to a broad range of heterogeneity scenarios showed that findings were qualitatively unchanged even in the hypothetical presence of high levels of study-to-study heterogeneity ([Fig. 6](#f6-cmo-8-2014-029){ref-type="fig"}). That is, even if 75% of the variability in estimates were because of study-specific differences in treatment effectiveness not chance, we would still find no statistically significant difference in OS, whereas enzalutamide would outperform abiraterone acetate in terms of time to PSA progression, radiographic PFS, and PSA RR.

In our study, we compared the interim analysis of AFFIRM[@b15-cmo-8-2014-029] and full analysis of COU-AA-301,[@b17-cmo-8-2014-029] which had somewhat different follow-up times, median 14.4 and 20.2 months, respectively. Hence, we repeated the indirect comparisons utilizing the interim analysis for both studies, AFFIRM[@b15-cmo-8-2014-029] and COU-AA-301,[@b16-cmo-8-2014-029] with comparable interim follow-up times, median 14.4 and 12.8 months, respectively. We found similar results; a non-significant improvement in OS with enzalutamide versus abiraterone acetate, but significant benefits of enzalutamide over abiraterone acetate in secondary outcomes: time to PSA progression, radiographic PFS, and PSA RRs ([Table 3](#t3-cmo-8-2014-029){ref-type="table"}).

Discussion
==========

In this indirect comparison study of enzalutamide and abiraterone acetate, we found no statistically significant difference in OS in patients with mCRPC post-docetaxel. However, enzalutamide showed significant benefits over abiraterone acetate for secondary outcomes: time to PSA progression, radiographic PFS, and PSA RRs. There were marginally more cardiac disorders with abiraterone acetate. In addition, both drugs had some adverse events that were unique to each: mineralocorticoid events for abiraterone acetate and a risk of seizures for enzalutamide.

A possible explanation for the superiority of enzalutamide over abiraterone could be the fact that prednisone administration was compulsory in the abiraterone study, COU-AA-301,[@b17-cmo-8-2014-029] whereas prednisone was not compulsory in the enzalutamide study, AFFIRM.[@b15-cmo-8-2014-029] Conventionally, prednisone is thought to have a therapeutic impact, potentially by exerting anti-cancer effects on its own or alleviating toxicities of other anti-tumor agents.[@b30-cmo-8-2014-029] Recently however, Richards et al. have shown that corticosteroids may activate the mutated androgen-receptor causing disease progression.[@b31-cmo-8-2014-029] Following that, Scher et al. conducted a post hoc analysis of the enzalutamide study, AFFIRM[@b15-cmo-8-2014-029], and found that patients given prednisone had poorer OS and reduced benefit of enzalutamide compared to patients without prednisone, with marginal differences observed for OS and more evident differences for PSA progression and radiographic PFS.[@b32-cmo-8-2014-029],[@b33-cmo-8-2014-029] Hence, compulsory administration of prednisone in the abiraterone study, COU-AA-301,[@b17-cmo-8-2014-029] could exert a greater attenuation of drug effect compared to AFFIRM,[@b15-cmo-8-2014-029] potentially explaining findings in our study of no significant difference in OS but significant benefits of enzalutamide over abiraterone in secondary endpoints.

The process of selecting a particular systemic therapy for patients with an incurable malignancy involves several different considerations, with the toxicity profile being one of the most important considerations. Enzalutamide is known to have off-site actions on GABA~A~ receptors in reducing seizure thresholds and hence should be used with close monitoring in patients with known seizure disorders or brain injury.[@b15-cmo-8-2014-029],[@b34-cmo-8-2014-029] Abiraterone acetate inhibits the steroidogenic pathway to cause mineralocorticoid disturbances and hence should be used with caution in patients with metabolite disturbances, renal failure, or congestive heart failure.[@b16-cmo-8-2014-029],[@b17-cmo-8-2014-029],[@b19-cmo-8-2014-029]

Ryan et al have recently reported evidence of significant improvement in OS and radiographic PFS for use of abiraterone acetate in mCRPC patients in the pre-chemotherapy setting.[@b35-cmo-8-2014-029] In the same mode, the PREVAIL trial comparing enzalutamide versus placebo in mCRPC patients in the pre-chemotherapy setting also reported favorable preliminary outcomes with significant improvement in OS and radiographic PFS.[@b36-cmo-8-2014-029],[@b37-cmo-8-2014-029] These provided a paradigm shift to the sequencing of therapeutic options and a question for future research to compare therapeutic outcomes of abiraterone acetate used in the pre- versus post-chemotherapy settings. However, a major limitation of these randomized phase III trials was that they were placebo-controlled, whereas for many patients with mCRPC, particularly symptomatic patients or asymptomatic patients with rapidly progressing disease, the standard of care would not be observation but rather treatment with chemotherapy. Even though abiraterone acetate was approved by the FDA for use in the pre-chemotherapy setting based on the results from this study, the optimal sequence of treatments remains poorly defined. To the best of our knowledge, there are no ongoing trials comparing abiraterone acetate to chemotherapy as first-line treatment for mCRPC.

Other therapeutic directions being explored for treatment of mCRPC include combining docetaxel with molecular targets for potential synergistic effects.[@b12-cmo-8-2014-029],[@b38-cmo-8-2014-029] However, Araujo et al. have recently reported no favorable outcomes for combination therapy involving docetaxel with tyrosine kinase inhibitor dasatinib.[@b39-cmo-8-2014-029] An ongoing phase 3 trial, SYNERGY (NCT01188187), is comparing docetaxel plus prednisone to docetaxel plus prednisone with custirsen sodium, a clusterin inhibitor.[@b40-cmo-8-2014-029] In addition, the combination of enzalutamide and abiraterone is also being investigated in a single arm phase 2 trial (NCT01650194).[@b41-cmo-8-2014-029]

The main limitation of our indirect comparison study is the assumption of no study-specific differences in the effectiveness of treatments. However, sensitivity analysis showed qualitatively unchanged findings across a broad range of potential study-to-study heterogeneity scenarios, as summarized by *I*[@b2-cmo-8-2014-029], ranging from 0 to 75%. Another limitation was the comparison of the interim analysis of AFFIRM[@b15-cmo-8-2014-029] and full analysis of COU-AA-301,[@b17-cmo-8-2014-029] which had different follow-up times. However, our sensitivity analysis showed that findings remained qualitatively unchanged when the interim analyses of each trial were compared.[@b15-cmo-8-2014-029],[@b16-cmo-8-2014-029] Nonetheless, this is the first study to compare (indirectly) the effects of enzalutamide and abiraterone acetate for the treatment of mCRPC post-docetaxel.

In conclusion, our indirect comparison suggests no statistically significant difference in OS between the two drugs. However, there is an indication that enzalutamide could be superior to abiraterone acetate in time to PSA progression, radiographic PFS, PSA RRs, and have a more favorable side effect profile than abiraterone acetate in the treatment of mCRPC post-docetaxel. The findings of this indirect comparison serve to be hypothesis-generating for future head-to-head trials comparing enzalutamide to abiraterone acetate in mCRPC post-docetaxel.
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###### 

Summary of individual trial characteristics.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TRIAL                                                    PATIENT GROUPS (N)                 MEDIAN FOLLOW-UP[a](#tfn1-cmo-8-2014-029){ref-type="table-fn"}   TREATMENT ARMS (N)                                                   OS[a](#tfn1-cmo-8-2014-029){ref-type="table-fn"}   TIME TO PSA PROGRESSION[a](#tfn1-cmo-8-2014-029){ref-type="table-fn"}   RADIOGRAPHIC PFS[a](#tfn1-cmo-8-2014-029){ref-type="table-fn"}   PSA RR[b](#tfn2-cmo-8-2014-029){ref-type="table-fn"}                                                                                   
  -------------------------------------------------------- ---------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------ ----- ------------------- ----------------------------------------------------- -----------------------
  AFFIRM[@b15-cmo-8-2014-029]                              Progressive CRPC post-docetaxel\   14.4                                                             Enzalutamide[c](#tfn3-cmo-8-2014-029){ref-type="table-fn"}\          18.4                                               0.63 (0.53--0.75)                                                       8.3                                                              0.25 (0.20--0.30)                                      8.3   0.40 (0.35--0.47)   54.0%[e](#tfn5-cmo-8-2014-029){ref-type="table-fn"}   76.41 (31.22--187.04)
                                                           (N = 1199)                                                                                          (n = 800)                                                                                                                                                                                                                                                                                                                                                                                               

  Placebo[c](#tfn3-cmo-8-2014-029){ref-type="table-fn"}\   13.6                                                                                                3.0                                                                                                                     2.9                                                                                                                                      1.5%[e](#tfn5-cmo-8-2014-029){ref-type="table-fn"}                                                                                     
  (n = 399)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  COU-AA-301[@b17-cmo-8-2014-029]                          Metastatic CRPC post-docetaxel\    20.2                                                             Abiraterone acetate[d](#tfn4-cmo-8-2014-029){ref-type="table-fn"}\   15.8                                               0.74 (0.64--0.86)                                                       8.5                                                              0.63 (0.52--0.78)                                      5.6   0.66 (0.58--0.76)   29.5%                                                 7.15 (4.53--11.28)
                                                           (N = 1195)                                                                                          (n = 797)                                                                                                                                                                                                                                                                                                                                                                                               

  Placebo[d](#tfn4-cmo-8-2014-029){ref-type="table-fn"}\   11.2                                                                                                6.6                                                                                                                     3.6                                                                                                                                      5.5%                                                                                                                                   
  (n = 398)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Reported in units of months.

RR defined as PSA decline ≥50%.

Concomitant administration with prednisone was allowed but not needed.

Concomitant administration with prednisone.

Denominator -- enzalutamide -- was 731; denominator -- placebo -- was 330.

###### 

Indirect comparisons of adverse events.

  ADVERSE EVENTS                                                    AFFIRM[@b15-cmo-8-2014-029]   COU-AA-301[@b17-cmo-8-2014-029]   INDIRECT COMPARISON                                                                                                               
  ----------------------------------------------------------------- ----------------------------- --------------------------------- ----------------------------------------------------------------- ----------- ----------- ------------------- ------------------- ------
  Fatigue                                                           269 (34%)                     116 (29%)                         1.24 (0.95--1.60)                                                 372 (47%)   174 (44%)   1.12 (0.88--1.43)   1.10 (0.77--1.57)   0.60
  Diarrhea                                                          171 (21%)                     70 (18%)                          1.28 (0.94--1.74)                                                 156 (20%)   58 (15%)    1.42 (1.02--1.98)   0.90 (0.57--1.41)   0.64
  Cardiac disorders[†](#tfn6-cmo-8-2014-029){ref-type="table-fn"}   49 (6%)                       30 (8%)                           0.80 (0.50--1.29)                                                 126 (16%)   46 (12%)    1.43 (1.00--2.06)   0.56 (0.31--1.01)   0.06
  Liver function test abnormalities                                 8 (1%)                        6 (2%)                            0.66 (0.23--1.92)                                                 89 (11%)    35 (9%)     1.30 (0.86--1.96)   0.51 (0.16--1.59)   0.25
  Fluid retention                                                   --                            --                                --                                                                261 (33%)   94 (24%)    1.57 (1.19--2.07)   --                  --
  Hypokalemia                                                       --                            --                                --                                                                143 (18%)   36 (9%)     2.19 (1.49--3.23)   --                  --
  Hypertension                                                      --                            --                                --                                                                88 (11%)    32 (8%)     1.42 (0.93--2.16)   --                  --
  Seizure                                                           5 (\<1%)                      0                                 Inf. (0.46--Inf.)[‡](#tfn7-cmo-8-2014-029){ref-type="table-fn"}   --          --          --                  --                  --

**Notes:**

Cardiac disorders were defined in COU-AA-301 to include any of the following: cardiac ischemia, myocardial infarction, supraventricular or ventricular tachyarrhythmias, cardiac failure, or other arrhythmia-related problems. In the AFFIRM study, cardiac disorder was defined more broadly as either any disorder or myocardial infarction.

**Abbreviations:** Inf., infinity;

OR, odds ratio.

###### 

Sensitivity analysis---comparison of indirect estimates of AFFIRM (interim analysis)[@b15-cmo-8-2014-029] with COU-AA-301 (full set[@b17-cmo-8-2014-029] and interim analysis[@b16-cmo-8-2014-029]).

  ---------------------------------------------------------------------------------------------------------------------------------------------------
                                                                            AFFIRM VERSUS COU-AA-301\   *P*      AFFIRM VERSUS COU-AA-301\   *P*
                                                                            (FULL SET)                           (INTERIM)                   
  ------------------------------------------------------------------------- --------------------------- -------- --------------------------- --------
  Median follow-up (month)                                                  14.4 versus 20.2            --       14.4 versus 12.8            --

  OS, HR (95% CI)                                                           0.85 (0.68--1.07)           0.17     0.97 (0.76--1.24)           0.81

  Time to PSA progression, HR (95% CI)                                      0.40 (0.30--0.53)           \<0.01   0.43 (0.32--0.59)           \<0.01

  Radiographic PFS, HR (95% CI)                                             0.61 (0.50--0.74)           \<0.01   0.60 (0.49--0.73)           \<0.01

  PSA response,[a](#tfn9-cmo-8-2014-029){ref-type="table-fn"} OR (95% CI)   10.69 (3.92--29.20)         \<0.01   10.89 (3.99--29.74)         \<0.01
  ---------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

RR defined as PSA decline ≥50%.
